LTA and cancer: In this regard, TNF and LT-α are commonly produced in the tumor microenvironment (reviewed in [54, 55]) and a modified version of recombinant TNF that preferentially localizes to tumors [56] is in Phase II/III clinical trials as a candidate cancer therapeutic [57].